IntelliGenome Wins INVIMA Approval for CRISPR-TB Test
HOUSTON, Texas & BOGOTÁ, Colombia, June 29, 2026 IntelliGenome, Inc. has received sanitary registration approval from Colombia’s National Institute...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
HOUSTON, Texas & BOGOTÁ, Colombia, June 29, 2026 IntelliGenome, Inc. has received sanitary registration approval from Colombia’s National Institute...
BALTIMORE, Maryland, June 29, 2026 CraniUS Therapeutics has received an initial $1.1 million award through the National Institutes of...
STAMFORD, Connecticut, June 30, 2026 Gainline Capital Partners has announced that its portfolio company M&M International, a leading manufacturer...
